Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Pentec Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia\u2122","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Hematology","graph2":"Approved"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lobe Sciences Initiates Phase 1 Clinical Trial of L-130","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lobe Sciences Provides Update on L-130 Clinical Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Lobe Sciences

    Menu

    Lobe Sciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Lobe Sciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lobe Sciences Provides Update on L-130 Clinical Program

              Details:

              The company’s lead clinical program, L-130 (psilocin Mucate), a proprietary stabilized conjugate drug candidate, 5-HT2A receptor agonist. It is being evaluating under Phase I clinical trial studies for the treatment of chronic cluster headaches.

              Lead Product(s): Psilocin Mucate

              Therapeutic Area: Neurology Product Name: L-130

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Lobe Sciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lobe Sciences Initiates Phase 1 Clinical Trial of L-130

              Details:

              L-130 (psilocin analogue), a proprietary stabilized psilocin analogue, which is invetigated for the treatment of chronic cluster headaches (CCH), the most predominant headache disorder within the group of trigeminal autonomic cephalgias (TACs).

              Lead Product(s): Psilocin Analogue

              Therapeutic Area: Neurology Product Name: L-130

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Lobe Sciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™

              Details:

              Pentec will receive the exclusive rights to distribute Altemia (docosahexaenoic acid ethyl ester), a proprietary oral formulation of emulsified docohexanoic acid, clinically evaluated to restore DHA levels and help reduce inflammation associated with SCD, in the United States.

              Lead Product(s): DHA

              Therapeutic Area: Hematology Product Name: Altemia

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Pentec Health

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY